Gates Foundation Plots A Fresh Metric For Market Access: Lives Saved
Gates Medical Research Institute’s Access To Affordability Model Combines Private Sector Know-How With The Public Good
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.
You may also be interested in...
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
In this installment of VC Playbook, profiling venture capital strategies in biopharma and medtech, In Vivo talks to Sofinnova’s Graziano Seghezzi about market access trends, Italy’s growing biotech offering and the perils of “health nationalism” to business partnering in the aftermath of COVID-19.
In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.